AMH Reliably Predicts Ovarian Reserve in Obese Women

[:en]Anti Mullerian Hormone (AMH) is widely used for the assessment of ovarian reserve. AMH is an ovarian reserve marker that gives an estimate of the remaining egg quantity. A normal AMH range is one to three; less than one means a low number of eggs remain. A high AMH means that an increased number of eggs remain, possibly due to Polycystic Ovarian Syndrome (PCOS).

Being overweight or obese has been shown to negatively impact the success of IVF and obstetrical outcomes. Recently, other medical sources found that patients with a Body Mass Index (BMI) at either extreme on the spectrum have less predictable AMH results.

Having worked with thousands of patients over the years, Fertility Centers of Illinois wanted to analyze this question in further detail to reach a definitive scientific conclusion in order to advance patient care.

The Fertility Centers of Illinois medical research team analyzed data over a two year period from 2,963 IVF patients who participated in AMH testing and BMI reporting. Study results conclusively found that AMH is a reliable predictor of ovarian reserve in obese and non obese women.

Study Findings:

  • Patients with a BMI of less than 30 had a mean AMH of 2.35 and retrieved an average of 13.1 oocytes (eggs).
  • Patients with a BMI of more than 30 had a mean AMH of 2.42 and retrieved an average of 12.5 oocytes.

As a benchmark, the optimal amount of eggs retrieved in one cycle is 10-15.

Study results also found that AMH, the number of retrieved oocytes, pregnancy rates, and live births were similar in both non obese and obese women in this study.

Complete study findings were presented to the American Society for Reproductive Medicine this past fall.

Fertility Authority interviewed Dr. Jennifer Hirshfeld-Cytron to learn more about the study in a recent article.

Interested in participating in an Fertility Centers of Illinois research study?

Fertility Centers of Illinois is home to two the world’s most advanced IVF laboratories and is often called on by pharmaceuticals companies to participate in research projects. Study participants may be eligible for discounted treatment services. Learn more about our current research studies.